Pharmaceuticals & Health Care – Pharmaceuticals: Second
Institutional Investor Research is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Pharmaceuticals & Health Care – Pharmaceuticals: Second

Alexandra Hauber & team

J.P. Morgan Cazenove

After leading the lineup for the past two years, the J.P. Morgan Cazenove quintet directed by Alexandra Hauber slips to second place; the crew, with analysts in London and Zurich, also claims a runner-up spot in Biotechnology. The researchers cover 20 stocks across the two sectors and are currently bullish on France’s Sanofi, which they upgraded from neutral to overweight in May, at €58.10, on the strength of its growing diabetes franchise, especially the drug Lantus. The stock had zipped to €71.39 by the end of the year, for a gain of 22.9 percent that beat the sector by 9.6 percentage points. “Despite the recent outperformance we still see further upside,” says Hauber. “The stock should go from a discount to the sector to a premium, and it remains a top pick for 2013.” Investors are impressed. “The J.P. Morgan team supplies consistent modeling across the large- and midcap names, as well as frequent updates on developments within the sector,” says one Boston-based money manager. — Leslie Kramer

Gift this article